Stock market announcement archive

LIFE: Purchase order on scanning electron microscope from Zeiss

November 28, 2023
Bergen, Norway, November 28th, 2023: Today, Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), can disclose that Lifecare has placed the purchase order for a SEM (abbreviation for Scanning Electron Microscope) from the German supplier Carl Zeiss AG. Reference is made to Lifecare’s list of trigger […]
Read more

LIFE: Successful ISO 13485 audit

November 20, 2023
Bergen, Norway, November 20th, 2023: Today, Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), can disclose that Lifecare Laboratory (Mainz, Germany) has been successfully audited as part of the upcoming ISO 13485 certification. Reference is made to Lifecare’s list of trigger events, as presented at the […]
Read more

Lifecare Q3 2023 report and webcast

November 13, 2023
Lifecare AS will present Q3 2023 financial and operational status in a webcast Tuesday 14 November. The webcast will be for all shareholders and interested parties at 10:30 – 11:15 CET. Lifecare's CEO Joacim Holter presents the company's Q3 report followed by a Q&A session where Joacim Holter will answer questions submitted in advance. Questions […]
Read more

LIFE: The European Patent Office intends to issue new Lifecare patent

November 8, 2023
Bergen, Norway, November 8th, 2023: Today, Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces that the European Patent Office (EPO) has reported its intent to grant Lifecare a new patent. Lifecare will review the examining division’s comments to the patent application and respond to the […]
Read more

LIFE: Lifecare receives regulatory approval to start LFC-SEN-002

November 7, 2023
Bergen, Norway, November 7th, 2023: Today, Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces that The Norwegian Food Safety Authority (NFSA) has awarded all necessary approvals to start LFC-SEN-002. Reference is made to Lifecare’s list of trigger events, as presented at the semi-annual report of […]
Read more

Lifecare – Valuation Report of the Sencell technology (CGM) for diabetes

November 1, 2023
Bergen, Norway, November 1st, 2023: Today, Lifecare AS (LIFE) (the “Company”), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), publishes a new valuation report of Lifecare’s CGM-technology. The report is enclosed and available on the bottom of this text. Commissioned by Lifecare, the life science technology valuation-company Xplico has […]
Read more

LIFE: Towards market readiness

August 23, 2023
Lifecare has shown major progress in our plan to bring the smallest ContinuousGlucose Monitor (CGM) system to the market. Testing in live tissue,implementation of Quality Management System and set up of manufacturingcapabilities form the three main pillars in our market-oriented development. - The results from studies concluded in 1H 2023 and the status of the […]
Read more

LIFE: Lifecare 2023 semi-annual report and webcast

August 22, 2023
Lifecare AS will present 1H 2023 financial and operational status in a webcastWednesday 23 August. The webcast will be for all shareholders and interestedparties at 09:30 - 10:15 CET.The Swedish research powered investment bank Redeye AB will host the webcast.Lifecare's CEO Joacim Holter presents the company's Semi Annual report followedby a Q&A with Redeye's analyst […]
Read more

Lifecare sensor longevity experiment concluded: 6 months operational lifetime

July 18, 2023
Lifecare’s Sencell Continuous Glucose Monitoring (CGM) sensor has reached an operational lifetime of more than 24 weeks (172 days), with a sensor chemistry shelf life of almost 27 weeks (187 days). This achievement confirms the Sencell CGM technology potential and validates Lifecares expectation of a minimum 6-month sensor longevity. The longevity results were achieved by […]
Read more

LIFE: CLINICAL STUDY RESULTS PRESENTED AT AMERICAN DIABETES ASSOCIATION SCIENTIFIC SESSIONS 2023

June 27, 2023
Data from Lifecare's Clinical Development Study LFC-SEN-001 was presented at theAmerican Diabetes Association (ADA) Scientific Sessions 2023. Lifecare's posterpresentation reveals the study background, methods, and results. The resultsinclude an impressive mean average of absolute error (MARD) of 9,6%, positioningLifecares's Sencell technology with an accuracy that is acceptable fortherapeutic (medical) decisions such as insulin dose adjustments. […]
Read more